Sign in
OKYO Stock Price, Chart, Stats & News
OKYO Pharma Limited
Save
OKYO Pharma Limited (OKYO) does not currently pay a dividend.
52.56M
Market cap
–
Current P/E
–
Forward P/E
OKYO chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 28.58% |
ROA | -99.34% |
ROE | 102.92% |
D/E | -0.05x |
Interest coverage ratio | -33.23x |
OKYO valuation
P/E | – |
P/S | – |
P/B | -16.76x |
P/CF | -18.48x |
P/FCF | -18.94x |
P/OCF | -18.48x |
PEG | -1.49x |
EV multiple | -6.55x |
About
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain.
Similar securities
Based on sector and market capitalization
Report issue